Julian Roy Levell

This inventor holds 15 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignees: Novartis Ag, Aventis Pharmaceuticals Inc., Constellation Pharmaceuticals, Inc.. Active years: 2001-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julian Roy Levell. Retrieved from https://idiyas.com/inventor/julian-roy-levell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 10)

% Patents Active = 80.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 6.2

ph-index = 6

Forward Citations = 71(Granted Patents)

Location History:

Royersford, PA (US) (2001)
Summit, NJ (US) (2005 - 2011)
Bernardsville, NJ (US) (2012)
Arlington, MA (US) (2014 - 2022)

Company Filing History:

Aventis Pharmaceuticals Inc.

patents

4 out of 56

Constellation Pharmaceuticals, Inc.

patents

4. 1 out of 330

Aventis Pharma Deutschland, Gmbh

patents

Years Active: 2001-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12172990 - Modulators of TREX1 (2024-12-24),

2. 11459315 - Modulators of methyl modifying enzymes, compositions and uses thereof (2022-10-04),

3. 11414384 - P300/CBP hat inhibitors (2022-08-16),

4. 11274090 - P300/CBP HAT inhibitors (2022-03-15),

5. 10112931 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2018-10-30),

6. 9688672 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2017-06-27),

7. 9434719 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2016-09-06),

8. 9309252 - Pyrrolopyrimidine compounds as inhibitors of CDK4/6 (2016-04-12),

9. 8957074 - Pyrrolopyrimidine compounds as inhibitors of CDK4/6 (2015-02-17),

10. 8957068 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2015-02-17),

11. 8828974 - Substituted propane phosphinic acid derivatives (2014-09-09),

12. 8183231 - Substituted propane phosphinic acid derivatives (2012-05-22),

13. 7947684 - 1-aroyl-piperidinyl benzamidines (2011-05-24),

14. 6977263 - Chemical compounds (2005-12-20),

15. 6281227 - Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds (2001-08-28),

Title: Innovations and Contributions of Julian Roy Levell

Introduction

Julian Roy Levell is a notable inventor based in Arlington, MA (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, Levell has made strides in developing compounds that address various medical conditions.

Latest Patents

Among his latest patents are "Modulators of TREX1," which includes compounds of Formula (I) and pharmaceutically acceptable salts and compositions that are useful for treating a variety of conditions associated with TREX1. Another significant patent is "Modulators of methyl modifying enzymes, compositions and uses thereof," which also features compounds of Formula (I) and pharmaceutically acceptable salts and compositions that are beneficial for treating conditions linked to methyl modifying enzymes.

Career Highlights

Levell has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Aventis Pharmaceuticals Inc. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Throughout his career, Levell has collaborated with esteemed colleagues such as Young Shin Cho and Yaping Wang, further enhancing the impact of his research and innovations.

Conclusion

Julian Roy Levell's contributions to the pharmaceutical industry through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to influence the development of treatments for various medical conditions.

Profile summary based on public USPTO records.